



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Brinsupri

Page: 1 of 2

Effective Date: 11/4/2025

Last Review Date: 10/1/2025

Applies to: Illinois
 Florida Kids

New Jersey
 Pennsylvania Kids

Maryland
 Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Brinsupri under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Applicable Drug List:

Binsupri

Policy/Guideline:

Criteria for Initial Approval:

Non-cystic fibrosis bronchiectasis (NCFB)

Authorization may be granted for the diagnosis of non-cystic fibrosis bronchiectasis (NCFB) in an adult or pediatric patient 12 years of age or older when the following criteria is met:

- The diagnosis was confirmed by a high-resolution computed tomography (HRCT) study of the chest.
- The patient has experienced a pulmonary exacerbation in the last 12 months (e.g., the presence of 3 or more of the following symptoms for at least 48 hours: increased cough; increased sputum production or change in sputum consistency; increased sputum purulence; increased breathlessness, decreased exercise tolerance, or both; fatigue, malaise, or both; or hemoptysis.)

Continuation of Therapy

Non-cystic fibrosis bronchiectasis (NCFB)

Authorization may be granted for the diagnosis of non-cystic fibrosis bronchiectasis (NCFB) in an adult or pediatric patient 12 years of age when the following criteria is met:

- The patient has experienced a positive response to therapy (e.g., reduction in pulmonary exacerbations from baseline).

Approval Duration and Quantity Restrictions:

Initial and Renewal Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Brinsupri [package insert]. Bridgewater, NJ: Insmmed Incorporated; August 2025.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Brinsupri

Page: 2 of 2

Effective Date: 11/4/2025

Last Review Date: 10/1/2025

Applies to: Illinois
 Florida Kids

New Jersey
 Pennsylvania Kids

Maryland
 Virginia

2. Lexicomp Online, Lexi-Drugs Online. Hudson, OH: UpToDate, Inc.; 2025; Accessed August 19, 2025.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed August 19, 2025.
4. Barker AF, Karamooz E. Non-Cystic Fibrosis Bronchiectasis in Adults – A Review. JAMA. 2025; 334(3): 253-264. doi: 10.1001/jama.2025.2680.
5. Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer. Respiratory Medicine 2020;166: <https://doi.org/10.1016/j.rmed.2020.105940>.